NanoLogix, Inc. Provides Operations Update and Notification of Shareholder Meeting

HUBBARD, OH--(Marketwire - July 28, 2009) - The company (PINKSHEETS: NNLX), following meetings in 2008 and 2009 with the US Environmental Protection Agency, has developed a test kit utilizing BNP™ technology for the rapid testing of water samples for specific strains of e-coli bacteria. The EPA is under a Federal Court order mandating sub-24 hour testing results for multiple microorganisms in beach waters by the year 2012.

During ongoing work on development of the water-quality testing kit for the EPA, recent company research has indicated that NanoLogix's BNP™ and BNC™ test kits may be used for detection and identification of viruses when combined with antibody-coated magnetic particles. This is potentially a major breakthrough for the company's diagnostic technology, adding significantly to the battery of detection capabilities currently available with BNP and BNC technology by moving beyond bacterial, spore and mold detection to include the realm of viruses. NanoLogix plans to contract with an Ohio-based research center with BSL-3 virology capabilities to perform further research on the efficacy of this approach.

The company will ship 500 diagnostic test kits to an international public health organization in Africa within the next week. This will be the first use of NanoLogix technology in Africa.

NanoLogix recently filed a patent application for their BNF™ (BioNanoFilter) test kit technology. The BNF complements the company's revolutionary BNP™ kit technology and provides the ability to work with filterable material such as liquid-phase medical lab samples, water, beverages, juices, etc. The BNF delivers similar time savings to the BNP kits, yet enables the testing of large-volume samples.

NanoLogix is currently proceeding with national patent filings for BNP technology in China, Japan, India, Brazil, the EU, and Russia. These filings are the next step in pursuing from the initial PCT (Patent Cooperation Treaty) filing done in 2007.

The company has retained the legal services of Arnold & Porter LLP (A&P), an international law firm headquartered in Washington, DC and with extensive experience working with biotech companies. A&P will be used to advise the company on matters such as corporate governance, licensing, and other issues related to future corporate direction.

Construction of the company's production cleanroom is projected to be completed in late August, with equipment installation to follow.

September 18th has been set as the tentative date for the 2009 NanoLogix shareholder meeting. Details of the meeting will follow in the near future.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical, Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.

More information on NanoLogix is available at: www.nanologix.com

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.